Microbial Metabolism of Atovaquone and Cytotoxicity of the Produced Phase I Metabolite
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pangarkar PA, Wanare RS, Tayde AM. Crystal modification of atovaquone in presence of polyethylene glycol (PEG) 4000. Int J Pharm Sci Rev. 2013;4(12):4632–41.
Dinter D, Gajski G, Garaj-Vrhovac V. An alkaline comet assay study on the antimalarial drug atovaquone in human peripheral blood lymphocytes: a study based on clinically relevant concentrations. J Appl Toxicol. 2013;33(1):56–62.
Kessl JJ, Moskalev NV, Gribble GW, Nasr M, Meshnick SR, Trumpower BL. Parameters determining the relative efficacy of hydroxy-naphthoquinone inhibitors of the cytochrome bc1 complex. Biochim Biophys Acta. 2007;1767(4):319–26.
Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O’Neill PM, Ward SA, Biagini CA. Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother. 2013;68(5):977–85.
Srivastava IK, Vaidya AB. A Mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43(6):1334–9.
Jones K, Ward SA. Biguanide-Atovaquone synergy against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002;46(8):2700–3.
Sek L, Boyd BJ, Charman WN, Porter CJ. Examination of the impact of a range of pluronic surfactants on the in vitro solubilization behavior and oral bioavailability of lipidic formulations of atovaquone. J Pharm Pharmacol. 2006;58:809–20.
Baramee A, Coppin A, Mortuaire M, Pelinski L, Tomavo S, Brocard J. Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum. Bioorg Med Chem. 2006;14(5):1294–302.
Zhou J, Duan L, Chen H, Ren X, Zhang Z, Zhou F, Liu J, Pei D, Ding K. Atovaquone derivatives as potent cytotoxic and apoptosis inducing agentes. Bioorg Med Chem Lett. 2009;19(17):5091–4.
Njuguna NM, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products-driven drug discovery. J Nat Prod. 2012;75(3):507–13.
Asha S, Vidyavathi M. Cunninghamella—a microbial model for drug metabolism studies—a review. Biotechnol Adv. 2009;27(1):16–29.
Ibrahim AK, Radwan MM, Ahmed SA, Slade D, Ross SA, ElSohly MA, Khan IA. Microbial metabolism of cannflavin A and B isolated from Cannabis sativa. Phytochemistry. 2010;71(8–9):1014–9.
Ouzzani J, Servy C, Bloy C, Ducrocq C. Fungal metabolite of naftazone inhibits nitrite production by activated murine macrophages. Bioorg Med Chem Lett. 1995;5(16):1825–8.
Parshikov IA, Freeman JP, Lay JO Jr, Beger RD, Williams AJ, Sutherland JB. Microbiological transformation of enrofloxacin by the fungus Mucor ramannianus. Appl Environ Microbiol. 2000;66(6):2664–7.
Alexandre V, Ladril S, Maurs M, Azerad R. Microbial models of animal drug metabolism Part 5. Microbial preparation of human hydroxylated metabolites of irbesartan. J Mol Catal B Enzym. 2004;29(1–6):173–9.
Duan M, Huang H, Li X, Chen X, Zhong D. Assignments of 1H and 13C NMR spectral data for ondansetron and its two novel metabolites, 1-hydroxy-ondansetron diastereoisomers. Magn Reson Chem. 2006;44(10):972–5.
Silva EO, Furtado NAJC, Aleu J, Collado IG. Terpenoid biotransformations by Mucor species. Phytochem Rev. 2013;12(4):857–76.
Meca G, Ritieni A, Mañes J. Reduction in vitro of the minor Fusarium mycotoxin beauvericin employing different strains of probiotic bactéria. Food Control. 2012;28(2):435–40.
Silva EO, Carvalho TC, Parshikov IA, Santos RA, Emery FS, Furtado NAJC. Cytotoxicity of lapachol metabolites produced by probiotics. Lett Appl Microbiol. 2014;59(1):108–14.
Jackson M, Karwoswski JP, Humphrey PE, Kohl WL, Barlow GJ, Tanaka SK. Calbistrins, novel antifungal agents produced by Penicillium restrictum. J Antibiot. 1993;46(1):34–8.
Rolan PE, Mercer AJ, Tate E, Benjamin I, Posner J. Disposition of atovaquone in humans. Antimicrob Agents Chemother. 1997;41(6):1319–21.